UCL IoO Annual Review for 2020-2021 academic year now live
We are delighted to launch our annual review for the last academic year.
You are here: vision-research.eu » News
We are delighted to launch our annual review for the last academic year.
New research could form the basis for developing life-changing therapies that limit the impact of diabetic eye disease—a condition that could potentially affect some 1.7 million Australians, suffering from type 1 and type 2 diabetes.
More than one-third of Americans have presbyopia, a gradual loss of near vision with age. Most people reach for eyeglasses or specialty contact lenses, but these are easily lost or can seem burdensome. Now, a promising nonsurgical treatment for presbyopia is on the horizon: topical eye drops.
Researchers at the IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology) developed an acoustic virtual reality-based archery game, enabling blind people to experience for the first time this type of technology, which is typically focused on vision.
Researchers have used MRI imaging to map visual brain activity in stroke survivors with sight loss that gives new hope for rehabilitation and recovery.
There’s a new way to deliver sight-saving treatment for wet age-related macular degeneration (wet AMD) and it may make living with the chronic eye condition a lot easier.
Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA). The model's development is described in the journal Stem Cell Reports.
Myopia progression may continue for more than one-third of young adults during the third decade of life, according to a study in JAMA Ophthalmology.
Congratulations to Mr Ian Murdoch for receiving an MBE in the New Year honours.
The biochemistry of vision is a complex process. The molecules supporting the visual pigments that allow us to see our surrounding reality have remained essentially invisible for scientists for a long time. The team led by Prof. Maciej Wojtkowski from the International Centre for Translational Eye Research (ICTER) has changed that, thanks to an innovative state-of-the art imaging device that they have developed.
At Hawaiian Eye 2022, Nancy Lurker, president and CEO of EyePoint Pharmaceuticals, discusses data from the Phase 1 DAVIO study of EYP-1901 for wet-AMD.
The University of Manchester, Seoul National University College of Medicine and Link Biologics Limited announced that promising preclinical data on the treatment of dry eye disease using a novel protein biological drug, Link_TSG6, have been published in Ocular Surface.
Daniel Hillier, leader of the IOB non-human primate platform, just won a Horizon NEURON grant totalling 1.2 million Euro for an amblyopia project.
Basil K. Williams Jr., MD, discussed how anterior segment OCT can be a “valid help adjunct” to clinical exams, although it is not a replacement for them. OCT can also help physicians differentiate between different lesions, Williams said, although histopathology is still needed to make a definitive diagnosis.
For the first time, University of California, Irvine researchers in collaboration with the Max-Planck Institute of Biochemistry, have revealed, at a molecular level, key structural determinants of the highly specialized rod outer segment (ROS) membrane architecture of the eye, which is instrumental to vision.